GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Ourofino SA (BSP:OFSA3) » Definitions » Short Percentage of Float

Ourofino (BSP:OFSA3) Short Percentage of Float


View and export this data going back to 2014. Start your Free Trial

What is Ourofino Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Ourofino's Short Percentage of Float

For the Drug Manufacturers - Specialty & Generic subindustry, Ourofino's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ourofino's Short Percentage of Float Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Ourofino's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Ourofino's Short Percentage of Float falls into.


;
;

Ourofino Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Ourofino SA (BSP:OFSA3) » Definitions » Short Percentage of Float
Comparable Companies
BSP:BLAU3 ZTS XTER:MRK LSE:HLN NSE:SUNPHARMA TSE:4502 XSWX:GALD XSWX:SDZ NSE:DIVISLAB HKSE:03692 XTAE:TEVA SHSE:688506 BOM:500087 SZSE:000538 TSE:4507 UTHR NSE:TORNTPHARM BOM:500124 NBIX BOM:543904
Traded in Other Exchanges
N/A
Address
Anhanguera Highway SP 330, Block C, 2nd floor, Km 298, Industrial District, Cravinhos, SP, BRA, 14140-000
Website
https://www.ourofino.com
Ourofino SA is engaged in research, development, production and sales of medicines, vaccines and other veterinary products. The company's reportable segments are Production animals, Companion animals, and International operations. It generates maximum revenue from the Production animals segment. The product portfolio includes Anticoccidials, Antimastitics, Biological, Ectoparasiticides, Endectocides, and others.

Ourofino Headlines

No Headlines